Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting one in 3,800 persons.

Vaderis Therapeutics has successfully closed a $152 million Series B financing round, launching the Phase 3 HEROIC study for engasertib aimed at treating HHT.

Vaderis Therapeutics has successfully raised $152 million in Series B funding, enabling the start of the HEROIC Phase 3 study for engasertib, targeting hereditary hemorrhagic telangiectasia.

Vaderis Therapeutics raised a Series B to run a Phase 3 study of its AKT inhibitor engasertib in a rare blood disorder called hereditary hemorrhagic telangiectasia.

EQT Life Sciences has invested $17.5 million in Vaderis Therapeutics as part of a $152 million Series B round aimed at advancing groundbreaking treatments for rare diseases.

$152 million Series B financing by private placement to select investors, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and Droia Provides the...

A trial of Vaderis' AKT inhibitor engasertib finds it could be the first effective treatment for rare disease hereditary haemorrhagic telangiectasia.

Hereditary hemorrhagic telangiectasia (HHT) can cause recurrent, severe epistaxis, as well as anemia and reduced quality of life. The disease remains without licensed therapies worldwide.In this...